三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
多纳非尼ZGDD3临床研究无进展生存期数据(ITT集)
多纳非尼ZGDD3临床研究无进展生存期数据(ITT集)
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:136KB
图片尺寸:1217*624
同报告图片
/
4
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
所属报告:
泽璟制药-688266-A股公司研究报告:三抗创新出海管线储备丰富-260625(43页).pdf
打包全文图表
相关数据
多纳非尼ZGDH3临床研究有效性数据(FAS集)
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
收藏
行业数据
2026-06-26
原图定位
查看详情
多纳非尼ZGDD3临床研究有效性数据(ITT集)
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
收藏
行业数据
2026-06-26
原图定位
查看详情
多纳非尼ZGDH3临床研究生存曲线(FAS集)
fCDnu4TliKsgICAgICAgfCDkuK3kvY3mgLvnlJ/lrZjmnJ/vvIjmnIjvvIkgfCA5NSXnva7kv6HljLrpl7QgICAgICAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLXwKfCDlpJrnurPpnZ7lsLznu4QgfCAxMi4xICAgICAgICAgICAgICB8ICgxMC4zLCAxMy40KSAgICAgIHwKfCDntKLmi4npnZ7lsLznu4QgfCAxMC4zICAgICAgICAgICAgICB8ICg5LjIsIDEyLjApICAgICAgIHwKCui1hOaWmeadpea6kO+8muWkmue6s+mdnuWwvOiNr+WTgeivtOaYjuS5pu+8jOWbveS/oeivgeWIuOe7j+a1jueglOeptuaJgOaVtOeQhg==
收藏
行业数据
2026-06-26
原图定位
查看详情
CARTITUDE-4: Overall MRD Negativity in Subgroups (ITT)
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: Secondary Endpoint (ITT) – Response
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
收藏
行业数据
2026-03-11
原图定位
查看详情
RBANS总分变化比较:完成者vS.ITT-MAR(p=0.032VS.0.012;调整β=4.75VS.4.67)
fCDliIbmnpDnsbvlnosgICAgICAgICB8IE4gICB8IEVHNTAx5Z2H5YC8zpQgfCDlronmhbDliYLlnYflgLzOlCB8CnwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS18Cnwg5a6M5oiQ6ICF5YiG5p6QICAgICAgIHwgNDMgIHwgMTAuNSAgICAgICB8IDQuMyAgICAgICAgIHwKfCBJVFQgLSBNQVLliIbmnpAgICAgfCA1NiAgfCAxMC40ICAgICAgIHwgNC40ICAgICAgICAgfAoK5pWw5o2u5p2l5rqQ77ya5Z+D5qC85p6X5Yy76I2v5L6b5Zu+
收藏
行业数据
2025-12-30
原图定位
查看详情
图24、多纳非尼与索拉非尼化学结构比较
fCDoja/nianlkI3np7AgICB8IOWFs+mUrue7k+aehOW3ruW8giAgICAgICAgICAgICAgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IOWkmue6s+mdnuWwvCAgIHwg5ZCr5LiJ5rCY55Sy5Z+677yILUNE4oKD77yJICAgICAgICAgfAp8IOe0ouaLiemdnuWwvCAgIHwg5a+55bqU5L2N572u5Li65pmu6YCa55Sy5Z+677yILUNI4oKD77yJIHwKCui1hOaWmeadpea6kO+8muWbveWutuWMu+eWl+S/nemanOWxgO+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
收藏
行业数据
2025-08-19
原图定位
查看详情
ALPINE研究终期分析时研究者评估的PFS(ITT人群)
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
收藏
行业数据
2025-04-18
原图定位
查看详情
IMpower150研究:ITT人群总生存期(OS)KM曲线
fCBUcmVhdG1lbnQgYXJtIHwgTWVkaWFuIE9TIHwgSFIgKDk1JSBDSSkgfCBwLXZhbHVlIHwKfC0tLXwtLS18LS0tfC0tLXwKfCBUZWNlbnRyaXErYmV2YWNpenVtYWIrcGFjbGl0YXhlbCtjYXJib3BsYXRpbiB8IDE5LjggbW8gfCAwLjc2ICgwLjYzLCAwLjk2KSB8IDAuMDA2MCB8CnwgVGVjZW50cmlxK3BhY2xpdGF4ZWwrY2FyYm9wbGF0aW4gfCAxOS41IG1vIHwgMC44NSAoMC43MSwgMS4wMykgfCAwLjA5ODMgfAp8IEJldmFjaXp1bWFiK3BhY2xpdGF4ZWwrY2FyYm9wbGF0aW4gfCAxNC45IG1vIHwgIHwgIHwKCui1hOaWmeadpea6kO+8muWfuuefs+iNr+S4muaOqOS7i+adkOaWme+8jOWkqemjjuivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-03-11
原图定位
查看详情
IMpower150研究:ITT人群无进展生存期(PFS)KM曲
fCBUcmVhdG1lbnQgYXJtIHwgTWVkaWFuIFBGUyB8IEhSICg5NSUgQ0kpIHwgcC12YWx1ZSB8CnwtLS18LS0tfC0tLXwtLS18CnwgVGVjZW50cmlxK2JldmFjaXp1bWFiK3BhY2xpdGF4ZWwrY2FyYm9wbGF0aW4gfCA4LjQgbW8gfCAwLjU5ICgwLjUwLCAwLjY5KSB8ICZsdDsgMC4wMDAxIHwKfCBUZWNlbnRyaXErcGFjbGl0YXhlbCtjYXJib3BsYXRpbiB8IDYuNyBtbyB8IDAuOTEgKDAuNzgsIDEuMDYpIHwgMC4yMTk0IHwKfCBCZXZhY2l6dW1hYitwYWNsaXRheGVsK2NhcmJvcGxhdGluIHwgNi44IG1vIHwgIHwgIHwKCui1hOaWmeadpea6kO+8muWfuuefs+iNr+S4muaOqOS7i+adkOaWme+8jOWkqemjjuivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-03-11
原图定位
查看详情
ITT人群PFS亚组分析(IRC评估)
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
收藏
行业数据
2025-02-10
原图定位
查看详情
IMpower150:疗效和安全性(ITT人群)
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
收藏
行业数据
2024-12-20
原图定位
查看详情
多纳非尼已有2大适应症获批上市,已被纳入医保开启放量模式
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
收藏
商业模式
2024-07-03
原图定位
查看详情
索拉非尼及仑伐替尼集采后销售额下滑,多纳非尼市占率提升(百万元)
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
收藏
竞争格局
2024-07-03
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
多纳非尼显著提高甲状腺癌患者的无进展生存期和客观缓解率。多纳非尼在甲状腺癌适应症中开展一项 ZGDD3 临床 3 期研究,临床共入组 191 名放射性碘难治、随机化前 14 个月内出现疾病进展的局部晚期/转移性分化型甲状腺癌患者,与安慰剂对比,按照 2:1 随机分组。意向性治疗分析集(ITT 集)中 56.0%的患者为女性、平均年龄 58.2 岁,18.3%的患者曾接受过酪氨酸激酶抑制剂治疗,97.4%的患者出现远端转移,多纳非尼组和安慰剂组分别有 28.1%和 34.9%的患者接受过累计放射性碘剂量≥600mCi 治疗。临床数据显示,多纳非尼治疗有效延缓疾病进展,mPFS 为 12.9 mo vs 6.4 mo,患者获得更好的客观缓解率,ORR 为 23.3% vs 1.7%。
行业数据
原图定位
当前图表所属:
泽璟制药-688266-A股公司研究报告:三抗创新出海管线储备丰富-260625(43页).pdf
财务预测与估值
盐酸吉卡昔替尼和芦可替尼临床有效性数据对比
JAK抑制剂在骨髓纤维化治疗中的竞争格局
多纳非尼ZGDH3临床研究安全性数据
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》